Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$241.0K+635.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harel Gadot
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 43
- Beta
- 1.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.82
Financials
Revenue
$241.0K+635.6%Net Income
$-5.63MEBITDA
$-5.60MFree Cash Flow
$-5.13MEPS (diluted)
$-0.08Shares Outstanding (diluted)
67.16M+12237.2%Operating Expenses
$5.54MCash & Debt
$67.37MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-13.14M | $-0.29 |
| 2024 | $0.00 | $-11.44M | $-0.73 |
| 2023 | $0.00 | $-10.74M | $-1.05 |
| 2022 | $0.00 | $-13.17M | $-1.81 |
| 2021 | $0.00 | $-11.31M | $-1.59 |
| 2020 | $0.00 | $-9.17M | $-1.29 |
| 2019 | $0.00 | $-7.25M | $-1.70 |
| 2018 | $0.00 | $-7.26M | $-0.81 |
| 2017 | $0.00 | $-7.59M | $-0.85 |
| 2016 | $0.00 | $-9.66M | $-10.14 |
| 2015 | $117.0K | $-36.41M | $-12.58 |
| 2014 | $1.01M | $-32.74M | $-858.60 |
| 2013 | $1.20M | $-26.44M | $-986.43 |
| 2012 | $1.37M | $-28.49M | $-1603.80 |
Valuation
MBOThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass.
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Microbot Medical® Highlights Growth Strategy Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
View source ↗ - Newszacks.com·56d ago·Negative
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise -7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.08 vs $-0.07miss
- Wed, May 13$-0.05 vs $-0.08beat
- Thu, Mar 26$-0.04 vs $-0.06beat
- Wed, Nov 12$-0.07 vs $-0.06miss
- Tue, Aug 12$-0.10 vs $-0.08miss
- Wed, May 14$-0.08 vs $-0.13beat
Estimates and results for MBOT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MBOT officers and directors.
- Bought
- $210k
- Sold
- $5.7m
6 trades
14 trades
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Gadot Harelsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MBOT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.